Hematologic abnormalities associated with vidarabine.
A report of hematologic abnormalities associated with administration of vidarabine in a neonate is presented. High doses of vidarabine (30 mg/kg/d) for the treatment of herpes simplex infection may have caused a decrease in hematocrit and platelet count. This case demonstrates the need to monitor hematologic indices during administration of vidarabine. The use of doses greater than 15 mg/kg/d is questioned.
D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced*; D006561:Herpes Simplex / Q000188:drug therapy; D006801:Humans; D007231:Infant, Newborn; D014740:Vidarabine / Q000009:adverse effects* / Q000627:therapeutic use
D014740:Vidarabine